Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax (2014 - 2026)

Ani Pharmaceuticals has disclosed Long-Term Deferred Tax across 13 years of filings, most recently posting $66.6 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $66.6 million, down 24.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.6 million (down 24.79% YoY), and the FY2025 annual result was $69.1 million, down 18.84% from the prior year.
• Long-Term Deferred Tax came in at $66.6 million for Q1 2026 at Ani Pharmaceuticals, down from $69.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $92.0 million in Q2 2025 to a low of $66.6 million in Q1 2026.
• The 5-year median for Long-Term Deferred Tax is $81.4 million (2022), against an average of $80.2 million.
• Across the five-year window, Long-Term Deferred Tax jumped 41.4% in 2022 and retreated 24.79% in 2026, its largest moves.
• Ani Pharmaceuticals' Long-Term Deferred Tax stood at $81.4 million in 2022, then climbed by 11.49% to $90.7 million in 2023, then dropped by 6.18% to $85.1 million in 2024, then slipped by 18.84% to $69.1 million in 2025, then declined by 3.64% to $66.6 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $66.6 million (Q1 2026), $69.1 million (Q4 2025), and $71.4 million (Q3 2025), per Business Quant data.